Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell lung cancer (NSCLC).
Benefits of combination docetaxel + ramucirumab
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell lung cancer (NSCLC).